|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||13.97 - 14.54|
|52 Week Range||8.31 - 32.74|
|PE Ratio (TTM)||-3.50|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
Joe Papa, chairman and CEO of Valeant Pharmaceuticals International, talks to Jim Cramer about his company's turnaround.
Valeant Pharmaceuticals International Inc. shares ticked higher in the extended session Wednesday after the drugmaker said that issues from a Food and Drug Administration inspection were being resolved. ...
LAVAL, Quebec, Aug. 16, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced the U.S. Food and Drug Administration (FDA) confirmed it intends to issue a Voluntary Action Indicated (VAI) inspection classification for its Bausch + Lomb manufacturing facility in Tampa, Fla. as part of a forthcoming Establishment Inspection Record for the facility. With this confirmation, manufacturing uncertainties related to current and upcoming regulatory submissions will be eliminated for products manufactured at the Tampa facility.